Table 2.

The association between use of antiplatelet or anticoagulant drugs and retinal/subretinal hemorrhage at baseline

			Unadjusted Analysis		Adjusted Analysis*
Use of anti-coagulant or anti-platelet drugs at baseline	n	Retinal/subretinal hemorrhage at baseline n (%)	Odds ratio (95% CI)	p-value	Odds ratio (95% CI)*	P-value
Any use of antiplatelet or anticoagulant drugs				0.09		0.21
No	557	332 (59.6%)	1.00		1.00
Yes	608	392 (64.5%)	1.23 (0.97 – 1.56)		1.18 (0.91 – 1.51)
Use of antiplatelet drugs				0.18		0.33
No	634	383 (60.4%)	1.00		1.00
Yes	531	341 (64.2%)	1.18 (0.93 – 1.49)		1.13 (0.88 – 1.45)
Use of anticoagulant drugs				0.22		0.33
No	1071	660 (61.6%)	1.00		1.00
Yes	94	64 (68.1%)	1.33 (0.85 – 2.09)		1.26 (0.79 – 2.00)
Combination on the use of antiplatelet or anticoagulant drugs				0.25		0.43
None	557	332 (59.6%)	1.00		1.00
Antiplatelet drugs only	514	328 (63.8%)	1.20 (0.93 – 1.53)	0.16	1.15 (0.89 – 1.49)	0.29
Anticoagulant drugs only	77	51 (62.2%)	1.33 (0.81 – 2.20)	0.27	1.24 (0.74 – 2.09)	0.41
Both antiplatelet drugs and anticoagulant drugs	17	13 (76.5%)	2.20 (0.71 – 6.83)	0.17	2.16 (0.68 – 6.85)	0.19
Type of antiplatelet or anticoagulant drug at baseline
None	557	332 (59.6%)	1.00		1.00
Aspirin	476	307 (64.5%)	1.23 (0.96 – 1.59)	0.11	1.20 (0.92 – 1.57)	0.18
Clopidogrel bisulfate	80	55 (68.8%)	1.49 (0.90 – 2.46)	0.12	1.66 (0.92 – 3.03)	0.10
Warfarin sodium	94	64 (68.1%)	1.45 (0.91 – 2.30)	0.12	1.46 (0.87 – 2.43)	0.15

OR = odds ratio, CI = confidence interval.

^*Adjusted by age (as continuous), gender, smoking status, diabetes, medical history of cardiovascular diseases, and CNV in fellow eye.